Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.
The phase 3 REDEFINE 2 trial has been evaluating once-weekly subcutaneous CagriSema, a fixed dose combination of cagrilintide ...
A class action lawsuit was filed against Novo Nordisk A/S (NVO) by Levi & Korsinsky on January 24, 2025. The plaintiffs ...
The stock was trading down more than 5.5% at the time of writing following the revelation that in the REDEFINE 2 trial, CagriSema (cagrilintide and semaglutide) achieved a weight loss of 15.7% ...
San Francisco, California-- (Newsfile Corp. - March 17, 2025) - Novo Nordisk A/S (NYSE: NVO) is facing a class-action lawsuit from investors who allege the pharmaceutical giant misled them about the ...
On December 20, 2024, Novo announced headline results for its REDEFINE-1 trial ... "2.4 mg cagrilintide and 2.4 mg semaglutide once-weekly," the maximum dosage of CagriSema contemplated by ...
Novo issued a press release announcing the below-expected results of their “REDEFINE 1” trial, “a 68-week efficacy and safety trial investigating subcutaneous CagriSema.” The trial showed ...
CagriSema – a combination of Novo ... Now, all eyes will be on the results from the second pivotal phase 3 trial, REDEFINE 2, in adults with type 2 diabetes and either obesity or overweight ...
The company said a Phase 3 trial showed that after 68 weeks, those who took CagriSema achieved a weight loss of 15.7%, compared with a weight loss of 3.1% for those taking a placebo. Tomi Kilgore ...
No benefits seen in terms of weight loss, diabetes remission, surgery safety. (HealthDay News) — Neoadjuvant semaglutide before metabolic and bariatric surgery (MBS) is not beneficial in terms ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback